See more : Metso Outotec Oyj (MOCORP.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Scilex Holding Company (SCLX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scilex Holding Company, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Sinopharm Tech Holdings Limited (8156.HK) Income Statement Analysis – Financial Results
- Extendicare Inc. (EXE.TO) Income Statement Analysis – Financial Results
- Gfinity plc (GFIN.L) Income Statement Analysis – Financial Results
- Element Nutritional Sciences Inc. (ELMT.CN) Income Statement Analysis – Financial Results
- Enplas Corporation (6961.T) Income Statement Analysis – Financial Results
Scilex Holding Company (SCLX)
About Scilex Holding Company
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 46.74M | 38.03M | 31.32M | 23.56M | 21.03M |
Cost of Revenue | 15.68M | 10.80M | 3.63M | 2.15M | 5.80M |
Gross Profit | 31.06M | 27.24M | 27.68M | 21.41M | 15.23M |
Gross Profit Ratio | 66.45% | 71.61% | 88.40% | 90.88% | 72.41% |
Research & Development | 12.75M | 9.05M | 9.20M | 9.96M | 85.52M |
General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 119.64M | 64.90M | 50.58M | 42.97M | 64.70M |
Other Expenses | 4.11M | 3.92M | 3.74M | 3.74M | 3.71M |
Operating Expenses | 136.49M | 77.87M | 63.52M | 56.67M | 153.93M |
Cost & Expenses | 152.17M | 88.67M | 67.16M | 58.82M | 159.73M |
Interest Income | 0.00 | 9.60M | 11.76M | 13.12M | 460.00K |
Interest Expense | 1.07M | 9.60M | 39.76M | 13.12M | 16.89M |
Depreciation & Amortization | 4.15M | 4.45M | 4.15M | 3.78M | 3.75M |
EBITDA | -109.10M | -9.30M | -44.88M | -31.48M | -134.49M |
EBITDA Ratio | -233.41% | -122.71% | -102.37% | -133.62% | -639.40% |
Operating Income | -105.43M | -50.63M | -35.84M | -35.26M | -138.70M |
Operating Income Ratio | -225.55% | -133.13% | -114.44% | -149.65% | -659.42% |
Total Other Income/Expenses | -8.89M | 27.27M | -52.58M | -12.31M | -39.90M |
Income Before Tax | -114.32M | -23.36M | -88.42M | -47.57M | -178.59M |
Income Before Tax Ratio | -244.57% | -61.42% | -282.34% | -201.92% | -849.10% |
Income Tax Expense | 13.00K | 4.00K | 5.00K | -53.00K | 2.00K |
Net Income | -114.33M | -23.36M | -88.42M | -47.52M | -178.59M |
Net Income Ratio | -244.59% | -61.43% | -282.35% | -201.69% | -849.11% |
EPS | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
EPS Diluted | -1.28 | -0.17 | -0.67 | -0.34 | -1.27 |
Weighted Avg Shares Out | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Weighted Avg Shares Out (Dil) | 130.30M | 134.23M | 132.86M | 141.10M | 141.10M |
Scilex Holding Company Announces that ZTlido® Achieves a Major Milestone - Over One Million Patients Treated Since its Launch - and Two Additional Milestones Met
Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the Treatment of Chronic Neck Pain¹
Scilex Holding Company Chief Executive Officer and President Issues Letter to Stockholders Highlighting 2023 Accomplishments and Outlook for 2024
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The Fiscal Year Ended December 31, 2023, Based On Currently Available Information
Scilex Holding Company Announces Filing of a New Drug Submission (NDS) to Health Canada's Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Scilex Holding Company Announces that According to Prescription Data from Symphony Health, ZTlido® is the Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing
Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.
Scilex Holding Company Announces Expanded Access to ELYXYB® By the Execution of First ELYXYB® Insurance Coverage Agreement with One of the Top Three National PBMs (Pharmacy Benefit Manager) for its Medicare Population
Scilex Holding Company announces that ZTlido® (lidocaine topical system) will be added as a preferred agent to the Medicaid Preferred Drug List (PDL) in two new states: one Midwestern and one Southern State
Source: https://incomestatements.info
Category: Stock Reports